Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 1—January 2017
CME ACTIVITY - Research

Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–20121

Sara Strollo2, Michail S. Lionakis, Jennifer Adjemian, Claudia A. Steiner, and D. Rebecca PrevotsComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (S. Strollo, M.S. Lionakis, J. Adjemian, D.R. Prevots); United States Public Health Service, Rockville, Maryland, USA (J. Adjemian); Agency for Healthcare Research and Quality, Rockville (C.A. Steiner)

Main Article

Table

Primary or secondary diagnosis for invasive candidiasis hospitalizations, United States, 2002–2012*

Diagnosis No. (%) hospital discharges, n = 138,433
Indicator of invasive candidiasis
Septicemia or sepsis 99,360 (72)
Complication of device, implant, or graft 62,092 (45)
Complication of surgical procedures or medical care
38,940 (28)
Underlying condition
Gastrointestinal disorders or conditions 63,470 (46)
Hypertension 54,094 (39)
Diabetes mellitus 35,689 (26)
Kidney disease 34,626 (25)
Cancer 33,359 (24)
Congestive heart failure 30,348 (22)
Nervous system disorders 26,220 (19)
Coronary atherosclerosis and other heart disease 20,085 (15)
Chronic obstructive pulmonary disease and bronchitis 23,850 (17)
Liver diseases 19,888 (14)
Esophageal disorders 14,625 (11)

*Neonates (<1 mo of age) were excluded. Data were provided by State Inpatient Databases through the Healthcare Cost and Utilization Project maintained by the US Agency for Healthcare Research and Quality. Diagnoses were classified by using Agency for Healthcare Research and Quality clinical classification software codes (17) and multiple International Classification of Diseases, 9th Revision, Clinical Modification codes and ranges.

Main Article

References
  1. Kullberg  BJ, Arendrup  MC. Invasive Candidiasis. N Engl J Med. 2015;373:1445–56. DOIPubMedGoogle Scholar
  2. Pappas  PG. Invasive candidiasis. Infect Dis Clin North Am. 2006;20:485–506. DOIPubMedGoogle Scholar
  3. Wisplinghoff  H, Ebbers  J, Geurtz  L, Stefanik  D, Major  Y, Edmond  MB, et al. Nosocomial bloodstream infections due to Candida spp. in the USA: species distribution, clinical features and antifungal susceptibilities. Int J Antimicrob Agents. 2014;43:78–81. DOIPubMedGoogle Scholar
  4. Magill  SS, Edwards  JR, Bamberg  W, Beldavs  ZG, Dumyati  G, Kainer  MA, et al.; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014;370:1198–208. DOIPubMedGoogle Scholar
  5. Yapar  N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014;10:95–105. DOIPubMedGoogle Scholar
  6. Doi  AM, Pignatari  AC, Edmond  MB, Marra  AR, Camargo  LF, Siqueira  RA, et al. Epidemiology and microbiologic characterization of nosocomial candidemia from a Brazilian national surveillance program. PLoS One. 2016;11:e0146909. DOIPubMedGoogle Scholar
  7. Pfaller  MA, Andes  DR, Diekema  DJ, Horn  DL, Reboli  AC, Rotstein  C, et al. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008. PLoS One. 2014;9:e101510. DOIPubMedGoogle Scholar
  8. Gudlaugsson  O, Gillespie  S, Lee  K, Vande Berg  J, Hu  J, Messer  S, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003;37:1172–7. DOIPubMedGoogle Scholar
  9. Wisplinghoff  H, Bischoff  T, Tallent  SM, Seifert  H, Wenzel  RP, Edmond  MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–17. DOIPubMedGoogle Scholar
  10. Eggimann  P, Garbino  J, Pittet  D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003;3:685–702. DOIPubMedGoogle Scholar
  11. Diekema  D, Arbefeville  S, Boyken  L, Kroeger  J, Pfaller  M. The changing epidemiology of healthcare-associated candidemia over three decades. Diagn Microbiol Infect Dis. 2012;73:45–8. DOIPubMedGoogle Scholar
  12. Myerowitz  RL, Pazin  GJ, Allen  CM. Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am J Clin Pathol. 1977;68:29–38. DOIPubMedGoogle Scholar
  13. Cleveland  AA, Farley  MM, Harrison  LH, Stein  B, Hollick  R, Lockhart  SR, et al. Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. Clin Infect Dis. 2012;55:1352–61. DOIPubMedGoogle Scholar
  14. Wilson  LS, Reyes  CM, Stolpman  M, Speckman  J, Allen  K, Beney  J. The direct cost and incidence of systemic fungal infections. Value Health. 2002;5:26–34. DOIPubMedGoogle Scholar
  15. Cleveland  AA, Harrison  LH, Farley  MM, Hollick  R, Stein  B, Chiller  TM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One. 2015;10:e0120452. DOIPubMedGoogle Scholar
  16. Healthcare Cost and Utilization Project. State Inpatient Databases, 2002–2012. Rockville (MD): Agency for Healthcare Research and Quality [cited 2016 Apr 14]. https://www.hcup-us.ahrq.gov/sidoverview.jsp
  17. Healthcare Cost and Utilization Project. Clinical Classifications Software (CCS) for ICD-9-CM, 2002–2012. Rockville (MD): Agency for Healthcare Research and Quality [cited 2016 Apr 14]. https://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
  18. Healthcare Cost and Utilization Project. Cost-to-charge files, 2002–2012. Rockville (MD): Agency for Healthcare Research and Quality [cited 2016 Apr 14]. https://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp
  19. Finkler  SA. The distinction between cost and charges. Ann Intern Med. 1982;96:102–9. DOIPubMedGoogle Scholar
  20. US Department of Labor. Bureau of Labor Statistics. Chained consumer price index for all urban consumers (C-CPI-U) 2002–2015, medical care [cited 2016 Apr 14]. http://www.bls.gov/data/
  21. Clancy  CJ, Nguyen  MH. Undiagnosed invasive candidiasis: incorporating non-culture diagnostics into rational prophylactic and preemptive antifungal strategies. Expert Rev Anti Infect Ther. 2014;12:731–4. DOIPubMedGoogle Scholar
  22. Asti  L, Newland  J, Zerr  D, Elward  A, Leckerman  K, Guth  R, et al. Multi-center validation of ICD-9 codes for candidemia in a pediatric population. In: Abstracts of the 48th Infectious Disease Society of America Meeting, Vancouver, British Columbia, Canada, Oct 22–24. Arlington (VA): Infectious Diseases Society of America; 2010. Abstract 561.
  23. Clancy  CJ, Nguyen  MH. Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis. 2013;56:1284–92. DOIPubMedGoogle Scholar
  24. Walker  TA, Derado  G, Cleveland  AA, Beldavs  ZG, Farley  LH. Socioeconomic determinants of racial disparities in candidemia incidence using geocoded data from the Emerging Infections Program (EIP), 2008–2014. In: Abstracts of the 65th Annual Epidemic Intelligence Service (EIS) Conference, Atlanta; May 2–5, 2016. Atlanta: Centers for Disease Control and Prevention; 2016. Abstract P2.11.
  25. Centers for Disease Control and Prevention (CDC). Vital signs: central line-associated blood stream infections—United States, 2001, 2008, and 2009. MMWR Morb Mortal Wkly Rep. 2011;60:243–8.PubMedGoogle Scholar
  26. Zaoutis  TE, Argon  J, Chu  J, Berlin  JA, Walsh  TJ, Feudtner  C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–9. DOIPubMedGoogle Scholar

Main Article

1Preliminary results from this study were presented at the IDWeek 2015 Conference; October 7–11, 2015; San Diego, California, USA.

2Current affiliation: American Cancer Society, Atlanta, Georgia, USA.

Page created: December 14, 2016
Page updated: December 14, 2016
Page reviewed: December 14, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external